Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (631-640 of 713) with videos related to

Pageof 72
Sort By:
American Journal of Hematology|May 31, 2017
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemiaElias Jabbour, Naval Guastad Daver, Nicholas James Short, et al.
Blood Advances|August 26, 2021
Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panelCarolina Pavlovsky, Virginia Abello Polo, Katia Pagnano, et al.
Haematologica|July 22, 2017
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndromeNaval Daver, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood|April 25, 2013
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationFarhad Ravandi, Mona Lisa Alattar, Michael R Grunwald, et al.
Blood|August 3, 2006
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemiaGuillermo Garcia-Manero, Hagop M Kantarjian, Blanca Sanchez-Gonzalez, et al.
American Journal of Hematology|January 5, 2017
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantationSameh Gaballa, Rima Saliba, Betul Oran, et al.
American Journal of Hematology|January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agentsElias Jabbour, Paolo Strati, Monica Cabrero, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemiaMichael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, et al.
Blood|October 22, 2009
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutationFranck E Nicolini, Michael J Mauro, Giovanni Martinelli, et al.
Scientific Reports|September 14, 2017
A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia PatientsHui-Jen Tsai, Shih Sheng Jiang, Wen-Chun Hung, et al.
Pageof 72

Showing results (631-640 of 713) with videos related to

Sort By:
Pageof 72
American Journal of Hematology|May 31, 2017
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemiaElias Jabbour, Naval Guastad Daver, Nicholas James Short, et al.
Blood Advances|August 26, 2021
Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panelCarolina Pavlovsky, Virginia Abello Polo, Katia Pagnano, et al.
Haematologica|July 22, 2017
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndromeNaval Daver, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood|April 25, 2013
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationFarhad Ravandi, Mona Lisa Alattar, Michael R Grunwald, et al.
Blood|August 3, 2006
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemiaGuillermo Garcia-Manero, Hagop M Kantarjian, Blanca Sanchez-Gonzalez, et al.
American Journal of Hematology|January 5, 2017
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantationSameh Gaballa, Rima Saliba, Betul Oran, et al.
American Journal of Hematology|January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agentsElias Jabbour, Paolo Strati, Monica Cabrero, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemiaMichael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, et al.
Blood|October 22, 2009
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutationFranck E Nicolini, Michael J Mauro, Giovanni Martinelli, et al.
Scientific Reports|September 14, 2017
A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia PatientsHui-Jen Tsai, Shih Sheng Jiang, Wen-Chun Hung, et al.
Pageof 72